GILD

In the past six months, Gilead Sciences' stock price has increased by over 12%. The company's Q1 2026 financial results showed better-than-expected revenue and adjusted EPS, with total product sales reaching $6.9 billion, a 5% year-over-year increase. HIV sales were a primary driver, up 10% year-over-year, with strong demand for Biktarvy and significant growth in the U.S. PrEP business. Oncology product sales also increased by 7% year-over-year. Despite the strong sales performance, the stock declined by 1.64% in after-hours trading following the Q1 earnings announcement, likely due to investor concerns regarding acquisition-related costs, as the company lowered its full-year 2026 adjusted EPS guidance. Gilead has been engaged in a significant M&A spree targeting oncology and immunology. The company did, however, raise its full-year 2026 product sales guidance to a range of $30.0 billion to $30.4 billion.